Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chemical chaperone screening for Pelizaeus-Merzbacher disease

ABSTRACT: We investigated the changes in the overall gene expression in MO3.13 cells induced by PLP1A243V and piracetam using RNA microarray analyses. We compared gene expression between PLP1WT and PLP1A243V and the expression profile in MO3.13 stably expressing PLP1A243V with/without piracetam.

ORGANISM(S): Homo sapiens

PROVIDER: GSE124034 | GEO | 2018/12/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Chemical chaperone screening for Pelizaeus-Merzbacher disease

Project description:Chemical chaperone screening for Pelizaeus-Merzbacher disease

| PRJNA510573 | ENA

Neurogenetics of Pelizaeus-Merzbacher disease.

Project description: Not available

| S-EPMC8167836 | biostudies-literature

Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease.

Project description: Not available

| S-EPMC6135742 | biostudies-literature

Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-08-22 | GSE111605 | GEO

Modeling the natural history of Pelizaeus-Merzbacher disease.

Project description: Not available

| S-EPMC4492172 | biostudies-other

Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease.

Project description: Not available

| S-EPMC7810164 | biostudies-literature

GJC2 promoter mutations causing Pelizaeus-Merzbacher-like disease.

Project description: Not available

| S-EPMC4183365 | biostudies-literature

Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease [scRNA-seq]

Project description:Pelizaeus-Merzbacher disease (PMD) is a fatal X-linked disorder caused by loss of myelinating oligodendrocytes and consequent hypomyelination. The underlying cellular and molecular dysfunctions are not fully defined, but therapeutic enhancement of oligodendrocyte survival could restore functional myelination in patients. Here we generated pure, scalable quantities of iPSC-derived oligodendrocyte progenitor cells (OPCs) from a severe mouse model of PMD, Plp1jimpy. Temporal phenotypic and transcriptomic studies defined an early pathological window characterized by endoplasmic-reticulum (ER) stress and cell death as OPCs exit their progenitor state. High-throughput phenotypic screening identified a compound, Ro 25-6981, which modulates the ER stress response and rescues mutant oligodendrocyte survival in jimpy, in vitro and in vivo, and in human PMD oligocortical spheroids. Surprisingly, increasing oligodendrocyte survival did not restore subsequent myelination, revealing a second pathological phase. Collectively, our work shows that PMD oligodendrocyte loss can be rescued pharmacologically and defines a need for multifactorial intervention to restore myelination.

2018-08-22 | GSE111599 | GEO

Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease [RNA-seq]

2018-08-22 | GSE111595 | GEO

Drug screening for Pelizaeus-Merzbacher disease by quantifying the total levels and membrane localization of PLP1.

Project description: Not available

| S-EPMC6510973 | biostudies-literature